The i-Port AdvanceTM injection port offers patients on multiple daily injections (MDI) a way to take their insulin without having to puncture their skin for each shot.REQUEST INFO
83% want to inject less2 79% skip injections2 74% discontinue insulin therapy3
The i-Port AdvanceTM injection port includes a built-in inserter, which enables a quick application. Once inserted, only a soft flexible tube, called a cannula, remains under the skin allowing for direct medication delivery from an insulin syringe or an insulin pen into the subcutaneous tissue.
The i-Port AdvanceTM injection port reduces patient anxiety and discomfort associated with MDI.4
100% helped decrease anxiety1
99% more beneficial than injections1
100% comfortable to wear1
In this video, you will learn how to apply, use, and remove the i-Port AdvanceTM injection port.
IMPORTANT SAFETY INFORMATION: i-PORT ADVANCE™ INJECTION PORT
i-Port AdvanceTM injection port is prescription-indicated for patients who administer, or to whom is administered, multiple daily subcutaneous injections of physician prescribed medications, including insulin. The device may remain in place for up to 72 hours to accommodate multiple drug injections without the discomfort of additional needle sticks. Site infection and/or irritation is a risk. Patients experiencing such symptoms should immediately consult their healthcare provider and/ or discontinue use. For complete details, please consult i-PortTM Advance product user guide.
Riley D, Raup G. Impact of a subcutaneous injection device on improving patient care. Nurse Manage. 2010;41(6):49–50 Prospective study conducted in an inpatient setting, in which 100 patients requiring multiple subcutaneous injections of insulin were offered i-Port; 39 of 100 patients reported needle anxiety prior to using i-Port.
American Association of Diabetes Educators. Injection impact report. http://www.injectionimpact.com/index.html. Published 2008. Accessed May 1, 2015;
Oliveria SA, Menditto LA, Yood MU, Koo YH, Wells KE, McCarthy BD. Barriers to the initiation of, and persistence with, insulin therapy. Curr Med Res Opin. 2007;23(12):3105–3112
FDA. i-Port Advance injection port. FDA approval. 2012.